Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for alleged violations of federal securities laws during the defined class period [1][2]. Class Definition - The lawsuit seeks to recover damages for all individuals and entities that purchased or acquired Jasper securities between November 30, 2023, and July 3, 2025 [2]. Case Details - The Complaint alleges that Jasper made materially false and misleading statements, including: - Lack of necessary controls and procedures for third-party manufacturers to comply with cGMP regulations [3]. - Increased risk of confounding results in ongoing studies, negatively impacting regulatory and commercial prospects of Jasper's products, particularly briquilimab [3]. - Heightened likelihood of disruptive cost-reduction measures [3]. - Overstated business and financial prospects, as well as clinical and commercial prospects of briquilimab [3]. - Defendants' statements regarding the Company's operations and prospects were materially false and misleading [3]. Next Steps - Interested parties can review the Complaint and have until November 18, 2025, to request appointment as lead plaintiff [4]. Legal Representation - The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. Firm Background - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered hundreds of millions for investors [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and lack of proper manufacturing controls [4][6]. Group 1: Legal Investigation and Claims - The firm is encouraging investors who suffered losses in Jasper between November 30, 2023, and July 3, 2025, to discuss their legal rights [1][4]. - A federal securities class action has been filed against Jasper, with a deadline of November 18, 2025, for investors to seek the role of lead plaintiff [4][8]. - The complaint alleges that Jasper and its executives made false statements regarding the company's manufacturing controls and the implications for its product, briquilimab [6][7]. Group 2: Company Performance and Stock Impact - On July 7, 2025, Jasper reported issues with a drug product lot used in clinical trials, leading to a significant drop in stock price by $3.73 per share, or 55.1%, closing at $3.04 per share [7]. - The company announced a halt in the development of briquilimab for asthma and SCID, contradicting previous claims of a strong financial position [7].

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential opportunities for traders [1] Premarket Gainers - PepGen Inc. (PEPG) is up 151% at $6.68 [3] - 22nd Century Group, Inc. (XXII) is up 27% at $1.93 [3] - Immuneering Corporation (IMRX) is up 23% at $11.36 [3] - uniQure N.V. (QURE) is up 10% at $52.58 [3] - Lithium Americas Corp. (LAC) is up 9% at $6.60 [3] - Jasper Therapeutics, Inc. (JSPR) is up 9% at $2.55 [3] - American Shared Hospital Services (AMS) is up 8% at $2.75 [3] - PSQ Holdings, Inc. (PSQH) is up 7% at $3.06 [3] - K Wave Media Ltd. (KWM) is up 7% at $2.48 [3] - ClearPoint Neuro, Inc. (CLPT) is up 5% at $20.48 [3] Premarket Losers - Transocean Ltd. (RIG) is down 14% at $3.11 [4] - Cyclerion Therapeutics, Inc. (CYCN) is down 12% at $2.83 [4] - CarMax, Inc. (KMX) is down 11% at $50.38 [4] - ARB IOT Group Limited (ARBB) is down 11% at $10.45 [4] - SHF Holdings, Inc. (SHFS) is down 10% at $6.49 [4] - Digital Brands Group, Inc. (DBGI) is down 10% at $6.21 [4] - Aqua Metals, Inc. (AQMS) is down 9% at $5.29 [4] - Akanda Corp. (AKAN) is down 8% at $3.96 [4] - Galecto, Inc. (GLTO) is down 8% at $3.88 [4] - Platinum Analytics Cayman Limited (PLTS) is down 7% at $11.12 [4]

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly misleading investors regarding the commercial prospects of its lead product candidate, briquilimab [1][2]. Allegations - The lawsuit claims that Jasper Therapeutics failed to disclose critical information about its manufacturing controls and procedures, which could affect the clinical trial results and the commercial viability of its products [2]. - Specific allegations include the lack of necessary controls for third-party manufacturers, increasing the risk of confounded study results, and overstating the company's financial and clinical prospects [2]. Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decline, closing at $3.04 per share [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs must file their papers by November 18, 2025, although participation is not required to be eligible for recovery [4]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5].

Group 1 - A class action lawsuit has been filed on behalf of investors who purchased Jasper Therapeutics, Inc. securities between November 30, 2023, and July 3, 2025 [1] - Investors have until November 18, 2025, to file a lead plaintiff motion [1] - The lawsuit is related to losses suffered by investors in Jasper Therapeutics, Inc. [1]

Core Viewpoint - Law Offices of Frank R. Cruz is encouraging investors of Jasper Therapeutics, Inc. (JSPR) to inquire about a potential securities fraud class action [1] Group 1 - The law firm is actively seeking investors who may have been affected by the alleged securities fraud involving Jasper Therapeutics [1] - The announcement indicates a growing concern regarding the company's practices and potential legal implications for investors [1] - This action reflects broader issues within the biotechnology sector, where companies may face scrutiny over their financial disclosures and operational transparency [1]

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from November 30, 2023, to July 3, 2025, seeking damages for affected investors [1][2]. Company Overview - Jasper Therapeutics is a clinical-stage biotechnology company focused on developing therapeutics for mast cell-driven diseases, including Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), and Asthma [4]. - The lead product candidate, briquilimab, is a monoclonal antibody aimed at blocking the stem cell factor (SCF) from binding to the CD117 (c-Kit) receptor, which is believed to be crucial for mast cell survival [4]. Financial Developments - In 2024, Jasper completed an oversubscribed financing round of $50 million to strengthen its balance sheet and support briquilimab's development, extending its cash runway through the third quarter of 2025 [4]. - Following a press release on July 7, 2025, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share due to issues related to a drug product lot used in clinical studies [8]. Clinical Trials and Issues - Jasper commenced a Phase 1b/2a clinical study for CSU (BEACON Study) in November 2023 and another for allergic asthma (ETESIAN Study) in December 2024 [4]. - On July 7, 2025, Jasper reported that results from the BEACON Study were confounded by issues with a specific drug product lot, leading to the halting of the ETESIAN Study and a pause in development for asthma and SCID [8][10]. Management and Operational Changes - Following the announcement of the drug lot issues, Jasper revealed a corporate reorganization, including a workforce reduction of approximately 50% and the halting of other clinical and preclinical programs to focus on briquilimab in chronic urticaria [10].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Jasper To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 Â (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept. ...

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from November 30, 2023, to July 3, 2025, seeking damages for affected investors [1][2]. Company Overview - Jasper Therapeutics is a clinical-stage biotechnology company focused on developing therapeutics for mast cell-driven diseases, including Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), and Asthma [4]. - The lead product candidate, briquilimab, is a monoclonal antibody aimed at blocking the stem cell factor (SCF) from binding to the CD117 (c-Kit) receptor, which is believed to deplete mast cells and provide clinical benefits for patients [4]. Financial Developments - In 2024, Jasper completed an oversubscribed financing round of $50 million to strengthen its balance sheet and support briquilimab's development, extending its cash runway through the third quarter of 2025 [4]. - Following a press release on July 7, 2025, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share due to issues related to a drug product lot used in clinical studies [8]. Clinical Trials and Issues - Jasper commenced a Phase 1b/2a clinical study for CSU (BEACON Study) in November 2023 and another for allergic asthma (ETESIAN Study) in December 2024 [4]. - On July 7, 2025, Jasper reported that results from the BEACON Study were confounded by issues with a specific drug product lot, leading to the halting of the ETESIAN Study and a pause in asthma development [8]. Management and Operational Changes - On July 9, 2025, Jasper announced a corporate reorganization, reducing its workforce by approximately 50% and halting other clinical and preclinical programs to focus on briquilimab in chronic urticaria [10]. - The Chief Medical Officer, Edwin Tucker, is set to depart from his role effective August 1, 2025 [10]. Legal Allegations - The lawsuit alleges that Jasper's executives made materially false and misleading statements regarding the company's operations and compliance with manufacturing regulations, which increased risks to the company's financial and clinical prospects [6][7].

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly making materially false and misleading statements regarding its business operations and compliance policies during the Class Period from November 30, 2023, to July 3, 2025 [2][3]. Allegation Details - The lawsuit claims that Jasper lacked necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the regulatory prospects of its products, particularly briquilimab [3]. - The failure to maintain proper manufacturing controls increased the likelihood of cost-reduction measures and overstated the Company's business and financial prospects [3]. Next Steps - Investors who purchased Jasper shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4].